| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/28/2002 | CA2456008A1 Stem cell differentiation |
| 02/28/2002 | CA2421062A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420274A1 Use of vitamin d derivatives as bone resorption inhibitors |
| 02/28/2002 | CA2420235A1 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon |
| 02/28/2002 | CA2420233A1 Method for identifying substances useful for treating inflammation using the response element to the i.kappa.b.alpha. ror receptor |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420087A1 Cripto tumour polypeptide |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419919A1 Novel imidazoline receptor homologs |
| 02/28/2002 | CA2419915A1 New sequences |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419580A1 Integrin receptor inhibitors |
| 02/28/2002 | CA2419454A1 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | CA2419310A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | CA2419274A1 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2418134A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | CA2418104A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | CA2417186A1 Microtubule-associated proteins and tubulins |
| 02/28/2002 | CA2416748A1 Improved specificity in treatment of diseases |
| 02/28/2002 | CA2415791A1 Treatment of wounds |
| 02/28/2002 | CA2415788A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| 02/28/2002 | CA2415182A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/28/2002 | CA2388061A1 Diagnosis and treatment of cardiovascular conditions |
| 02/28/2002 | CA2317305A1 Method of enhancing chondrocyte cell growth and glycosaminoglycan production |
| 02/27/2002 | EP1181935A2 Agent for treating mental disorders associated with cerebrovascular disorders |
| 02/27/2002 | EP1181933A2 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 02/27/2002 | EP1181932A2 Therapeutic compositions comprising excess enantiomer of amlodipine |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181376A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181358A2 Methods and materials for generating sh3 domains with tailored binding properties |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181310A1 Chemokine receptor ccr3 antagonists |
| 02/27/2002 | EP1181304A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| 02/27/2002 | EP1181294A1 Novel derivatives and analogues of galanthamin |
| 02/27/2002 | EP1181291A2 Dna methyltransferase inhibitors |
| 02/27/2002 | EP1181289A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181283A1 Diaminothiazoles and their use for inhibiting protein kinases |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181278A1 Cyclic amine derivatives and their uses |
| 02/27/2002 | EP1181275A1 Thio-oxindole derivatives |
| 02/27/2002 | EP1181274A1 Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| 02/27/2002 | EP1181271A2 Naphthalene ureas as glucose uptake enhancers |
| 02/27/2002 | EP1181269A1 Cell proliferation inhibitors |
| 02/27/2002 | EP1181266A1 Squaric acid derivatives as cell adhesion molecules |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181048A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor |
| 02/27/2002 | EP1181042A1 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area |
| 02/27/2002 | EP1181035A2 Substantially oil-free cyclosporin compositions |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181030A2 Tanacetum parthenium extract |
| 02/27/2002 | EP1181025A2 Molecular complexes presenting high affinity binding with respect to monocyte derived cells and their uses in therapy |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP1181014A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 02/27/2002 | EP1181010A1 Pharmaceutical chewing gum formulations |
| 02/27/2002 | EP1180938A2 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 02/27/2002 | EP0970105B1 Process for preparing carboxamido-4-azasteroids |
| 02/27/2002 | EP0927178B1 Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 02/27/2002 | EP0892789B1 Irreversible inhibitors of tyrosine kinases |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | EP0825991B1 Diaryldiamine derivatives and their use as delta opioid (ant)-agonists |
| 02/27/2002 | EP0687251B1 1,3-dihydroindol-2-one derivatives substituted in position 3 by a nitrogen group as vasopressin and/or ocytocine agonists and/or antagonists |
| 02/27/2002 | CN1337964A Novel aralkyl amines of spirofuropyridines useful in therapy |
| 02/27/2002 | CN1337963A Pirazino (aza) indole derivatives |
| 02/27/2002 | CN1337962A Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 02/27/2002 | CN1337961A Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors |
| 02/27/2002 | CN1337960A Piperdine and piperazine derivatives as inhibitors of the ABETA fibril formation |
| 02/27/2002 | CN1337959A 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 02/27/2002 | CN1337958A Compounds and methods for modulation of estroglen receptors |
| 02/27/2002 | CN1337956A New Morpholinobenzamide salts |
| 02/27/2002 | CN1337952A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 02/27/2002 | CN1337949A Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid as TACE inhibitor |
| 02/27/2002 | CN1337947A Acetylenic sulfonamide thiol TACE inhibitors |
| 02/27/2002 | CN1337945A Alkynyl containing hydroxamic acid compounds as TACE inhibitors |
| 02/27/2002 | CN1337944A Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid as TACE inhibitors |
| 02/27/2002 | CN1337932A Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treamtent of respiratory diseases |
| 02/27/2002 | CN1337851A Converting COX-2 inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors |
| 02/27/2002 | CN1337850A Amide derivatives for antiangiogenic and/or antitumorgenic use |
| 02/27/2002 | CN1337233A Chinese mineral medicine for both oral taking and external use |
| 02/27/2002 | CN1337228A Application of lipoic acid for improving biological utilization ratio of mineral salt |
| 02/27/2002 | CN1079833C Recombinant P53 adenovirus method and compositions |
| 02/27/2002 | CN1079796C Novel N-7-heterocyclyl pyrrolo [2,3-D] pyridines and their use |
| 02/27/2002 | CN1079792C 酶抑制剂 Inhibitors |
| 02/27/2002 | CN1079679C Cascade polymer complexes, its preparation process and medicine containing said complexes |
| 02/27/2002 | CN1079672C Oral liquid alendronate formulations |
| 02/27/2002 | CN1079671C Combination treatment for inhibiting bone loss |
| 02/27/2002 | CN1079668C Injectable liposumal pharmaceutical preparation |
| 02/27/2002 | CN1079660C Miniming trichomadesis with anti-fungus compound and halogeno-anti-bacteria compound |
| 02/26/2002 | US6350907 Matrix metalloprotease inhibitors |
| 02/26/2002 | US6350880 Crystalline or crystallized acid addition salt of losartan and purification method of losartan |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350856 Cytokine suppressive anti-inflammatory drug binding protein |